Cardior Pharmaceuticals Gmbh
Clinical trials sponsored by Cardior Pharmaceuticals Gmbh, explained in plain language.
-
New drug aims to heal hearts after attack – trial results awaited
Disease control CompletedThis study tested a new medicine called CDR132L in 294 people who had a recent heart attack and had weak heart pumping (ejection fraction 45% or less). Participants received one of two doses of CDR132L or a placebo, added to standard care, for 6 months. The goal was to see if the…
Phase: PHASE2 • Sponsor: Cardior Pharmaceuticals GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New heart failure drug shows early promise in small trial
Disease control CompletedThis early-stage study tested a new drug called CDR132L in 28 people with stable heart failure caused by reduced blood flow to the heart. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and research…
Phase: PHASE1 • Sponsor: Cardior Pharmaceuticals GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC